Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,431.62 6.77 0.04%
S&P 500 1,865.54 3.23 0.17%
NASDAQ 4,099.88 13.66 0.33%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

INNATE PHARMA: INITIATES IPH43 PROGRAM TO DEVELOP FIRST-IN-CLASS ANTI-MICA ANTIBODY



INNATE PHARMA: INITIATES IPH43 PROGRAM TO DEVELOP FIRST-IN-CLASS ANTI-MICA
ANTIBODY

  * MICA validated as a novel target for antibody drug development in solid
    tumors
  * IPH43 program now aims at selection and optimization of the best
    development candidate

MARSEILLE, France, Nov. 15, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the
"Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company
developing first-in-class drug candidates for cancer and inflammatory
diseases, announces the initiation of a new program to develop an anti-MICA
therapeutic antibody in oncology. The program, named IPH43, is the newest to
emerge from Innate Pharma's discovery platform.

MICA is a highly polymorphic ligand of the NK cell activating receptor NKG2D.
MICA is specifically expressed on several highly prevalent solid tumors
including breast, colorectal and lung. Innate Pharma has generated a panel of
high affinity antibodies recognizing all forms of MICA which is now being
tested and optimized to select the best development candidate.

Nicolai Wagtmann, CSO of Innate Pharma, said: "MICA's very clean expression
profile on tumor cells and not healthy cells makes it an exciting target for
cancer. Like with lirilumab, we successfully generated antibodies overcoming
target polymorphism, which is a major challenge and a pre-requisite for
development. We now look forward to applying our state-of-the-art
immunopharmacology and antibody-engineering platforms to further advance IPH43
towards clinical development."

Hervé Brailly, CEO of Innate Pharma, added: "Together with the recent start of
IPH4102 development, the launch of the IPH43 program illustrates Innate
Pharma's creativity and ability to spot novel targets for development of
first-in-class antibody candidates in immuno-oncology. Our discovery effort is
a key element for value creation. We generated three first-in-class candidates
brought to clinic with pharma partners and we are pleased to now progress a
second wave of these projects towards the clinic."

A poster on this program was presented at the Society for Immunotherapy of
Cancer (SITC) Annual Meeting, November 7-10, 2013, National Harbor, MD, USA:
"Targeting MICA with therapeutic antibodies for the treatment of cancer",
Saturday, November 9 from 1:00 pm - 2:00 pm and 6:15 pm - 7:15 pm, Poster 42.
The poster is available on Innate Pharma's website.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drug candidates for cancer and inflammatory diseases.

The Company specializes in the development of novel monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approaches have led to licensing agreements with Novo
Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 84 employees as at September
30, 2013.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code   FR0010331421
Ticker code IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                ATCG Press
Laure-Hélène Mercier         Marielle Bricman
Director, Investor Relations  
Phone: +33 (0)4 30 30 30 87  Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com  mb@atcg-partners.com

Press Release: http://hugin.info/155662/R/1743331/586393.pdf
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement